Inducible Production of Recombinant Human Flt3 Ectodomain Variants in Mammalian Cells and Preliminary Crystallographic Analysis of Flt3 Ligand-receptor Complexes

Overview

Journal Acta Crystallogr Sect F Struct Biol Cryst Commun

Date 2011 Mar 12

PMID 21393836

Citations 6

Authors

Kenneth Verstraete

Bert Remmerie

Jonathan Elegheert

Beatrice Lintermans

Guy Haegeman

Peter Vanhoenacker

Kathleen Van Craenenbroeck

Savvas N Savvides

Affiliations

Soon will be listed here.

Abstract

The extracellular complex between the haematopoietic receptor Flt3 and its cytokine ligand (FL) is the cornerstone of signalling cascades that are central to early haematopoiesis and the immune system. Here, efficient protocols for the production of two ectodomain variants of human Flt3 receptor, Flt3D1-D5 and Flt3D1-D4, for structural studies are reported based on tetracycline-inducible stable cell lines in HEK293S cells deficient in N-acetylglycosaminyltransferase I (GnTI-/-) that can secrete the target proteins with limited and homogeneous N-linked glycosylation to milligram amounts. The ensuing preparative purification of Flt3 receptor-ligand complexes yielded monodisperse complex preparations that were amenable to crystallization. Crystals of the Flt3D1-D4-FL and Flt3D1-D5-FL complexes diffracted to 4.3 and 7.8 Å resolution, respectively, and exhibited variable diffraction quality even within the same crystal. The resulting data led to the successful structure determination of Flt3D1-D4-FL via a combination of molecular-replacement and density-modification protocols exploiting the noncrystallographic symmetry and high solvent content of the crystals.

Citing Articles

Engineering and crystal structure of a monomeric FLT3 ligand variant.

Pannecoucke E, Raes L, Savvides S Acta Crystallogr F Struct Biol Commun. 2021; 77(Pt 4):121-127.

PMID: 33830077 PMC: 8034431. DOI: 10.1107/S2053230X21003289.

Generating Recombinant Antibodies to Membrane Proteins through Phage Display.

Huang R, Kiss M, Batonick M, Weiner M, Kay B Antibodies (Basel). 2019; 5(2).

PMID: 31557992 PMC: 6698964. DOI: 10.3390/antib5020011.

Structural Activation of Pro-inflammatory Human Cytokine IL-23 by Cognate IL-23 Receptor Enables Recruitment of the Shared Receptor IL-12Rβ1.

Bloch Y, Bouchareychas L, Merceron R, Skladanowska K, Van den Bossche L, Detry S Immunity. 2017; 48(1):45-58.e6.

PMID: 29287995 PMC: 5773378. DOI: 10.1016/j.immuni.2017.12.008.

Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma.

Verstraete K, Peelman F, Braun H, Lopez J, Van Rompaey D, Dansercoer A Nat Commun. 2017; 8:14937.

PMID: 28368013 PMC: 5382266. DOI: 10.1038/ncomms14937.

Structural basis of the proinflammatory signaling complex mediated by TSLP.

Verstraete K, van Schie L, Vyncke L, Bloch Y, Tavernier J, Pauwels E Nat Struct Mol Biol. 2014; 21(4):375-82.

PMID: 24632570 DOI: 10.1038/nsmb.2794.

References

Parcells B, Ikeda A, Simms-Waldrip T, Moore T, Sakamoto K . FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia. Stem Cells. 2006; 24(5):1174-84. DOI: 10.1634/stemcells.2005-0519. View

Stirewalt D, Radich J . The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003; 3(9):650-65. DOI: 10.1038/nrc1169. View

Keller S, Pojer F, Heide L, Lawson D . Molecular replacement in the 'twilight zone': structure determination of the non-haem iron oxygenase NovR from Streptomyces spheroides through repeated density modification of a poor molecular-replacement solution. Acta Crystallogr D Biol Crystallogr. 2006; 62(Pt 12):1564-70. DOI: 10.1107/S0907444906040169. View

Monneret C . Histone deacetylase inhibitors. Eur J Med Chem. 2005; 40(1):1-13. DOI: 10.1016/j.ejmech.2004.10.001. View

Yao F, Svensjo T, Winkler T, Lu M, Eriksson C, Eriksson E . Tetracycline repressor, tetR, rather than the tetR-mammalian cell transcription factor fusion derivatives, regulates inducible gene expression in mammalian cells. Hum Gene Ther. 1998; 9(13):1939-50. DOI: 10.1089/hum.1998.9.13-1939. View

Drexler H, Quentmeier H . FLT3: receptor and ligand. Growth Factors. 2004; 22(2):71-3. DOI: 10.1080/08977190410001700989. View

Heras B, Martin J . Post-crystallization treatments for improving diffraction quality of protein crystals. Acta Crystallogr D Biol Crystallogr. 2005; 61(Pt 9):1173-80. DOI: 10.1107/S0907444905019451. View

McClanahan T, Culpepper J, Campbell D, Wagner J, Mattson J, Tsai S . Biochemical and genetic characterization of multiple splice variants of the Flt3 ligand. Blood. 1996; 88(9):3371-82. View

Lyman S, James L, Vanden Bos T, de Vries P, Brasel K, Gliniak B . Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell. 1993; 75(6):1157-67. DOI: 10.1016/0092-8674(93)90325-k. View

10.

Vagin A, Teplyakov A . Molecular replacement with MOLREP. Acta Crystallogr D Biol Crystallogr. 2010; 66(Pt 1):22-5. DOI: 10.1107/S0907444909042589. View

11.

Maroc N, Rottapel R, Rosnet O, Marchetto S, Lavezzi C, Mannoni P . Biochemical characterization and analysis of the transforming potential of the FLT3/FLK2 receptor tyrosine kinase. Oncogene. 1993; 8(4):909-18. View

12.

Chang V, Crispin M, Aricescu A, Harvey D, Nettleship J, Fennelly J . Glycoprotein structural genomics: solving the glycosylation problem. Structure. 2007; 15(3):267-73. PMC: 1885966. DOI: 10.1016/j.str.2007.01.011. View

13.

Barash S, Wang W, Shi Y . Human secretory signal peptide description by hidden Markov model and generation of a strong artificial signal peptide for secreted protein expression. Biochem Biophys Res Commun. 2002; 294(4):835-42. DOI: 10.1016/S0006-291X(02)00566-1. View

14.

Brasel K, Escobar S, Anderberg R, de Vries P, Gruss H, Lyman S . Expression of the flt3 receptor and its ligand on hematopoietic cells. Leukemia. 1995; 9(7):1212-8. View

15.

Kikushige Y, Yoshimoto G, Miyamoto T, Iino T, Mori Y, Iwasaki H . Human Flt3 is expressed at the hematopoietic stem cell and the granulocyte/macrophage progenitor stages to maintain cell survival. J Immunol. 2008; 180(11):7358-67. DOI: 10.4049/jimmunol.180.11.7358. View

16.

Aricescu A, Lu W, Jones E . A time- and cost-efficient system for high-level protein production in mammalian cells. Acta Crystallogr D Biol Crystallogr. 2006; 62(Pt 10):1243-50. DOI: 10.1107/S0907444906029799. View

17.

Zheng R, Levis M, Piloto O, Brown P, Baldwin B, Gorin N . FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. Blood. 2003; 103(1):267-74. DOI: 10.1182/blood-2003-06-1969. View

18.

Lavagna C, Marchetto S, Birnbaum D, Rosnet O . Identification and characterization of a functional murine FLT3 isoform produced by exon skipping. J Biol Chem. 1995; 270(7):3165-71. DOI: 10.1074/jbc.270.7.3165. View

19.

Kiyoi H, Naoe T . Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation. Int J Hematol. 2006; 83(4):301-8. DOI: 10.1532/IJH97.06071. View

20.

Griffith J, Black J, Faerman C, Swenson L, Wynn M, Lu F . The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell. 2004; 13(2):169-78. DOI: 10.1016/s1097-2765(03)00505-7. View